Home / Business and Economy / Jazz Pharma Earnings: Sales Beat, EPS Miss Surprise
Jazz Pharma Earnings: Sales Beat, EPS Miss Surprise
2 Sep
Summary
- Q2 adjusted EPS missed estimates due to acquired IPR&D expenses.
- Total revenues rose 16% year over year, beating revenue estimates.
- Xywav net sales increased 11% to nearly $502 million in Q2.
Jazz Pharmaceuticals' second-quarter 2026 adjusted earnings per share (EPS) came in at $5.71, falling short of the Zacks Consensus Estimate of $6.04. This shortfall was largely attributed to $77 million in acquired in-process research and development (IPR&D) expenses, which reduced adjusted EPS by 94 cents.
Despite the EPS miss, the company reported a notable 16% year-over-year increase in total revenues, reaching $1.21 billion. This performance surpassed the Zacks Consensus Estimate of $1.11 billion, fueled by robust sales from its oncology and neuroscience product portfolios.
Net product sales were particularly strong, totaling $1.16 billion, a 17% increase from the previous year and exceeding analyst expectations. The sleep franchise, consisting of Xyrem and Xywav, contributed significantly, with combined sales rising 11% to nearly $502 million. Xywav sales alone grew 13% to $471 million, supported by sustained demand and a high quarterly patient increase.
